Related Experiment Video
Updated: Jul 10, 2025
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
7.9K
Structure-Based Virtual Screening for Novel Inhibitors Targeting KRAS G12C
1Berkshire School, 245 N Undermountain Rd, Sheffield, MA 01257, United States.
Studies in Health Technology and Informatics
|November 26, 2023
Summary
Researchers identified eight novel inhibitors targeting the KRAS G12C oncoprotein. These potential cancer drugs bind to the P2 pocket, trapping KRAS in an inactive state for future therapeutic development.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Mutated KRAS proteins, particularly KRAS G12C, are key drivers in various cancers.
- Developing targeted therapies for KRAS-driven cancers remains a significant challenge.
- There is a critical need for novel therapeutic strategies to inhibit oncogenic KRAS.
Purpose of the Study:
- To identify novel small molecules that inhibit the KRAS G12C oncoprotein.
- To explore inhibitors targeting the P2 pocket of KRAS G12C.
- To provide a foundation for the development of next-generation cancer therapeutics.
Main Methods:
- Structure-based virtual screening was employed to discover potential KRAS G12C inhibitors.
- Quantitative analysis was used to assess the efficacy of identified compounds.
- Inhibitors were designed to bind to the P2 pocket, stabilizing the inactive GDP-bound state.
Main Results:
- A set of eight potential novel inhibitors targeting KRAS G12C was identified.
- These compounds demonstrated the potential to trap KRAS G12C in an inactive conformation.
- The study provides a promising starting point for further drug development.
Conclusions:
- The identified inhibitors represent a promising new class of drugs for KRAS G12C-mediated cancers.
- Targeting the P2 pocket offers an effective strategy for KRAS G12C inhibition.
- These findings advance the understanding of KRAS G12C inhibition and cancer therapy.
